Systemic sclerosis, Idiopathic inflammatory myopathy / myositis, ANCA-Associated Vasculitis
NKTXNkarta TherapeuticsCatalyst overview
Research summary
This catalyst tracks a Phase 1 data readout for NKX019 (CAR NK cell therapy) in Systemic sclerosis, Idiopathic inflammatory myopathy / myositis, ANCA-Associated Vasculitis. The expected timing is based on the latest available company guidance and may change.
Ntrust-2 trial. 6/27/24- IND cleared. 12/5/24- Open to enroll patients. 8/12/25- Preliminary clinical data in H2 2025. 11/10/25:- Ntrust-2 enrollment streamlined under combined iDSMB; second dose-escalation cohort enrolling; preliminary data expected 2026. 03/25/26:- Ntrust-2 enrollment ongoing; patients now dosed at 4B cells; initial data planned at 2026 medical conference. 04/15/26:- FDA agreed outpatient dosing and redosing. Ntrust-2 adds rheumatoid arthritis cohort; initial data expected at 2026 medical meeting. 05/12/26:- Enrollment ongoing at 4B-dose in Ntrust-2; initial multi-indication data planned at 2026 medical meeting. 08/10/26:- Outpatient dosing underway; Ntrust-2 enrollment continues; initial data expected in 2026.
Verification
Confirm timing and program details against the company announcement or filing.